Advertisement

[News] SSO 2024

April, 04, 2024 | Select Oncology Journal Articles

A phase 1 trial of short-course pre-operative chemoradiotherapy (CRT) as part of total neoadjuvant therapy in potentially resectable gastric cancer was presented by Brian Badgwell (MD Anderson Cancer Center, Houston, TX, USA). 24 patients received 30 Gy radiation in 10 fractions plus concurrent capecitabine or fluorouracil, followed by chemotherapy for 2 months and then surgery. The primary objective was safety. CRT-related adverse events included grade 3–4 lymphopenia (eight [33%] patients) and grade 3 anaemia (one [4%] patient).

For Additional News from OncWeekly – Your Front Row Seat To The Future of Cancer Care –

Advertisement

LATEST

Advertisement

Sign up for our emails

Trusted insights straight to your inbox and get the latest updates from OncWeekly

Privacy Policy